mrsa

Mupirocin (BRL-4910A) is a RNA synthetase inhibitor antibacterial. It has shown excellent activity against gram-positive staphylococci and streptococci.

Benzyldodecyldimethylammonium chloride dihydrate can be used as an insecticide reagent. It can target drug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus, multidrug-resistant Pseudomonas aeruginosa, etc., in a concentration-dependent manner.

Mupirocin calcium hydrate is an antibiotic produced by Pseudomonas fluorescens, showed a high level of activity against staphylococci and streptococci and against certain gram-negative bacteria

MAC-545496 is a glycopeptide-resistance-associated protein R (GraR) inhibitor, is an antivirulence agent.

Dalbavancin (BI-397), a novel second-generation lipoglycopeptide antibiotic, possesses in vitro activity against a variety of Gram-positive pathogens including methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE),Dalbavancin inhibits Staphylococcus aureus and Bacillus anthracis with MIC90s of 0.06 μg/mL and 0.25 μg/mL, respectively

Ceftobiprole medocaril (BAL5788), the parenteral prodrug of Ceftobiprole, is a broad-spectrum cephalosporin effective against Methicillin-resistant Staphylococcus aureus (MRSA).

Neogambogic acid, an active ingredient in garcinia, can inhibit the growth of some solid tumors [resulting in an anticancer effect], and may be responsible for the inhibition of proliferation of human breast cancer cell line MCF-7 cells.

Ceftaroline fosamil (TAK-599) is a cephalosporin, with activity against Gram-positive pathogens.

PK150 shows oral bioavailability and antibacterial activity against several pathogenic strains at submicromolar concentrations.

Sanguisorbigenin (Tomentosolic acid) is a natural antimicrobial agent that inhibits methicillin-resistant Staphylococcus aureus (MRSA).

Ceftobiprole (Ro 63-9141) is a β-lactam antibacterial agent that exhibits potent bactericidal activity by binding to PBPs, inhibiting transpeptidation and formation of bacterial cell walls, leading to cell lysis and death, with a MIC90 value of 2 μg/mL against methicillin-resistant Staphylococcus aureus.

Anti-MRSA agent 21 (Compound 27) demonstrates antibacterial activity against MRSA with a minimum inhibitory concentration (MIC) of 1 μM. It disrupts the bacterial cell membrane and increases reactive oxygen species.

Anti-MRSA agent 23 (compound 11) is a potent agent against methicillin-resistant Staphylococcus aureus. This compound exhibits both antibacterial and antibiofilm properties. It facilitates the healing and reconstruction of MRSA-infected skin wounds by reducing bacterial load, alleviating inflammation, and promoting angiogenesis.

Anti-MRSA agent 22 (Compound 5a) is an effective antibacterial compound against MRSA with a minimum inhibitory concentration (MIC) of 6 µg/mL. It exhibits high binding affinity to FabI, with a value of -11.19.

Anti-MRSA agent 24 (compound 6K) is an antibacterial compound that targets methicillin-resistant Staphylococcus aureus (MRSA), demonstrating significant inhibitory effects on strains resistant to penicillin.

Anti-MRSA agent 25 (Compound 10c) is an antibacterial compound with a minimum inhibitory concentration (MIC) of 0.25 μg/mL against methicillin-resistant Staphylococcus aureus (MRSA). Its antimicrobial activity is achieved by inhibiting biofilm formation, disrupting the cell wall (interacting with peptidoglycan and lipoteichoic acid), acting on the cell membrane (causing depolarization, increasing permeability, and compromising integrity), reducing metabolic activity, interfering with cellular redox homeostasis, and binding to DNA. Anti-MRSA agent 25 holds potential for research in the field of anti-infective therapeutics.

MRSA/VRE-IN-1 (Compound 3e) is an inhibitor targeting methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE), with MIC/MBC values of 3.6/7.3 µM for VRE and 7.3/14.6 µM for MRSA. It is applicable in research focused on anti-infection studies.

Anti-MRSA agent 27 (compound 4a) is a potent antimicrobial agent against methicillin-resistant Staphylococcus aureus (MRSA) with a minimum inhibitory concentration (MIC) of 0.0975 μmol/L. It effectively disrupts MRSA biofilms and inhibits the production of hemolysins.

Anti-MRSA agent 26 (compound 21) is an antibiotic that serves as a potent MRSA inhibitor. It exhibits a MIC of <0.015 μg/mL for MSSA and a MIC range of 0.015-0.06 μg/mL for MSSA, MRSE, and VRE. In a murine model of Staphylococcus aureus skin infection, Anti-MRSA agent 26 effectively clears the infection. It is a 7-deazapurine pyridine with potential application for treating topical infections caused by multidrug-resistant Gram-positive bacteria.

Anti-MRSA agent 9 (compound 39) exhibits antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) isolated from clinical samples, with a minimum inhibitory concentration (MIC) of 1 μg/ml. Additionally, Anti-MRSA agent 9 demonstrates anti-MRSA efficacy in vivo.

Anti-MRSA agent 10 (Compound 2d) is a cephalosporin derivative with antibacterial properties. It displays minimal resistance and shows low cytotoxicity in HUVEC and HBZY-1 cells.

Anti-MRSA agent 11 demonstrates strong activity against both fluoroquinolone-sensitive strain USA500 and resistant MRSA strain Mu50, with a MIC value of 0.39 μg/mL. It also possesses a favorable in vivo half-life and safety profile.

Anti-MRSA agent 14 (Compound C17) exhibits antibacterial activity against MRSA and in a MRSA-infected mouse skin model. It demonstrates greater potential against MRSA compared to Norfloxacin. Anti-MRSA agent 14 disrupts cell membranes and inhibits metabolism. Its antibacterial MIC values against S. aureus ATCC 6538, S. aureus ATCC 29213, S. epidermidis ATCC 12228, and MRSA are 1, 2, 2, and 1 μM, respectively.

Anti-MRSA agent 13 (Compound 9b) is an effective antimicrobial against methicillin-resistant Staphylococcus aureus (MRSA) with a minimal inhibitory concentration (MIC) of 0.5–2 μg/mL for clinically isolated strains. It exhibits excellent biocompatibility, stable plasma tolerance, and a low propensity for resistance. Anti-MRSA agent 13 disrupts the cell wall and membrane, reduces metabolic activity, induces oxidative damage, and impairs DNA function, leading to MRSA death through a multi-target synergistic mechanism.